期刊
FERTILITY AND STERILITY
卷 97, 期 1, 页码 28-U84出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.fertnstert.2011.09.024
关键词
Polycystic ovary syndrome; hirsutism; contraception; pregnancy complications; quality of life; insulin resistance; type 2 diabetes; metabolic syndrome; cardiovascular disease; cancer
资金
- Andromed
- Ardana
- Ferring
- Glycotope
- Genovum
- IBSA
- Merck (MSD)
- Merck Serono
- Organon
- Pantharei Bioscience
- PregLem
- Schering
- Schering Plough
- Serono
- Wyeth
- Merck Sharp Dohme
- U.S. National Institutes of Health
- Merck Serono S. A.
- Bayer
- Abbott
- Abbott laboratories
- Quest Diagnostics
- Merck, Sharp and Dohme Co.
- Medical Research Council [1241993] Funding Source: researchfish
- MRC [G0802782] Funding Source: UKRI
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females, with a high prevalence. The etiology of this heterogeneous condition remains obscure, and its phenotype expression varies. Two widely cited previous ESHRE/ASRMsponsored PCOS consensus workshops focused on diagnosis (published in 2004) and infertility management (published in 2008), respectively. The present third PCOS consensus report summarizes current knowledge and identifies knowledge gaps regarding various women's health aspects of PCOS. Relevant topics addressed-all dealt with in a systematic fashion-include adolescence, hirsutism and acne, contraception, menstrual cycle abnormalities, quality of life, ethnicity, pregnancy complications, long-term metabolic and cardiovascular health, and finally cancer risk. Additional, comprehensive background information is provided separately in an extended online publication. (Fertil Steril (R) 2012;97:28-38. (C) 2012 by American Society for Reproductive Medicine.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据